R
Rajneesh Pathania
Researcher at Georgia Regents University
Publications - 16
Citations - 620
Rajneesh Pathania is an academic researcher from Georgia Regents University. The author has contributed to research in topics: Mammary tumor & Cancer. The author has an hindex of 8, co-authored 16 publications receiving 483 citations. Previous affiliations of Rajneesh Pathania include Guru Angad Dev Veterinary and Animal Sciences University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis
Rajneesh Pathania,Sabarish Ramachandran,Selvakumar Elangovan,Ravi Padia,Pengyi Yang,Senthilkumar Cinghu,Rajalakshmi Veeranan-Karmegam,Pachiappan Arjunan,Jaya P. Gnana-Prakasam,Fulzele Sadanand,Lirong Pei,Chang Sheng Chang,Jeong Hyeon Choi,Huidong Shi,Santhakumar Manicassamy,Puttur D. Prasad,Suash Sharma,Vadivel Ganapathy,Raja Jothi,Muthusamy Thangaraju +19 more
TL;DR: An essential role for DNMT1 is uncovered in MaSC and CSC maintenance and theDNMT1-ISL1 axis is identified as a potential therapeutic target for breast cancer treatment.
Journal ArticleDOI
Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth
Rajneesh Pathania,Sabarish Ramachandran,G. Mariappan,Priyanka Thakur,Huidong Shi,Jeong Hyeon Choi,Santhakumar Manicassamy,Ravindra Kolhe,Puttur D. Prasad,Suash Sharma,Bal L. Lokeshwar,Vadivel Ganapathy,Muthusamy Thangaraju +12 more
TL;DR: It is suggested that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer.
Journal ArticleDOI
The Niacin/Butyrate Receptor GPR109A Suppresses Mammary Tumorigenesis by Inhibiting Cell Survival
Selvakumar Elangovan,Rajneesh Pathania,Sabarish Ramachandran,Sudha Ananth,Ravi Padia,Ling Lan,Nagendra Singh,Pamela M. Martin,Lesleyann Hawthorn,Puttur D. Prasad,Vadivel Ganapathy,Muthusamy Thangaraju +11 more
TL;DR: Findings suggest that GPR109A is a tumor suppressor in mammary gland and that pharmacologic induction of this gene in tumor tissues followed by its activation with agonists could be an effective therapeutic strategy to treat breast cancer.
Journal ArticleDOI
Multi-omic Profiling Reveals Dynamics of the Phased Progression of Pluripotency.
Pengyi Yang,Pengyi Yang,Sean J. Humphrey,Sean J. Humphrey,Senthilkumar Cinghu,Rajneesh Pathania,Andrew J. Oldfield,Dhirendra Kumar,Dinuka Perera,Jean Yee Hwa Yang,David E. James,Matthias Mann,Raja Jothi +12 more
TL;DR: The dynamics of pluripotent state transitions underlying pre- to post-implantation epiblast differentiation and kinase-substrate networks reveal signaling cascades, dynamics, and crosstalk in embryonic stem cells transitioning from naive to primed pluripotency.
Journal ArticleDOI
Molecular Mechanism of SLC5A8 Inactivation in Breast Cancer
Selvakumar Elangovan,Rajneesh Pathania,Sabarish Ramachandran,Sudha Ananth,Ravi Padia,Sonne R. Srinivas,Ellappan Babu,Lesleyann Hawthorn,Patricia V. Schoenlein,Thomas Boettger,Sylvia B. Smith,Puttur D. Prasad,Vadivel Ganapathy,Muthusamy Thangaraju +13 more
TL;DR: The results provide the tumor-suppressive role of SLC5A8 and identify the oncogenic HRAS as a mediator of tumor-associated silencing of this tumor suppressor in mammary glands suggest that pharmacological approaches to reactivate SLC 5A8 expression in tumor cells have potential as a novel therapeutic strategy for breast cancer treatment.